UBS Group AG — Director's Dealing 2026

Jan 16, 2026

National Storage Mechanism | Additional information

RNS Number : 2889P

UBS O'Connor

16 January 2026

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	UBS O'Connor [i]
Company dealt in	AVADEL PHARMACEUTICALS PLC
Class of relevant security to which the dealings being disclosed relate (Note 2)	€0.01 ordinary shares
Date of dealing	15 January 2026

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities	1,000,182     1.0268%
(2) Derivatives (other than options)	109,578     0.1125%
(3) Options and agreements to purchase/sell
Total	1,109,760     1.1393%

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long			Short
	Number		(%)	Number		(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)

(b)      Derivatives transactions (other than options transactions)

Product name,e.g. CFD	Nature of transaction(Note 6)	Number of relevant securities(Note 7)	Price per unit(Note 5)
CFD	Buy	13,695	21.5323 USD

(c)     Options transactions in respect of existing relevant securities

Purchase/sale	Number of relevant securities	Price per unit (Note 5)

(i)       Writing, selling, purchasing or varying

Product name,e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name,e.g. call option	Number of securities	Exercise price per unit (Note 5)

(c)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction(Note 8)	Details	Price per unit(if applicable) (Note 5)

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)      NO

Date of disclosure	16 January 2026
Contact name	Richard Howard
Telephone number	+44 (0)207 568 9128
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

---

[i] Comprising the O'Connor business acting under

UBS Asset Management (UK) Ltd

UBS Asset Management (Hong Kong) Ltd

UBS Asset Management (Singapore) Ltd

UBS Asset Management (Americas) LLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ITPEADFKFSXKEFA